Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alexa B Schrock

Showing results (11-20 of 130) with videos related to

Pageof 13
Sort By:
Lung Cancer (Amsterdam, Netherlands)|July 6, 2017
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinibViola W Zhu, J Jean Cui, Maria Fernandez-Rocha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic ProfilingAngel Qin, Adrienne Johnson, Jeffrey S Ross, et al.
JCO Precision Oncology|April 9, 2026
Clinicogenomic Landscape and Function of <i>PIK3CA</i>, <i>AKT1</i>, and <i>PTEN</i> Mutations in Breast CancerJacqueline J Tao, Saumya D Sisoudiya, Hanna Tukachinsky, et al.
Cancer Research Communications|March 16, 2023
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal CancerRyon P Graf, Virginia Fisher, James Creeden, et al.
Lung Cancer (Auckland, N.Z.)|May 31, 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burdenAnkur R Parikh, Siraj M Ali, Alexa B Schrock, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
The Oncologist|May 17, 2017
Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNAAndrea Z Lai, Alexa B Schrock, Rachel L Erlich, et al.
JCO Precision Oncology|March 7, 2024
Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung CancerJeff Yorio, Katherine T Lofgren, Jessica K Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2016
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 SkippingSai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, et al.
The Oncologist|January 19, 2021
RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal CancerAlexa B Schrock, Jessica K Lee, Jaideep Sandhu, et al.
Pageof 13

Showing results (11-20 of 130) with videos related to

Sort By:
Pageof 13
Lung Cancer (Amsterdam, Netherlands)|July 6, 2017
Identification of a novel T1151K ALK mutation in a patient with ALK-rearranged NSCLC with prior exposure to crizotinib and ceritinibViola W Zhu, J Jean Cui, Maria Fernandez-Rocha, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 30, 2018
Detection of Known and Novel FGFR Fusions in Non-Small Cell Lung Cancer by Comprehensive Genomic ProfilingAngel Qin, Adrienne Johnson, Jeffrey S Ross, et al.
JCO Precision Oncology|April 9, 2026
Clinicogenomic Landscape and Function of <i>PIK3CA</i>, <i>AKT1</i>, and <i>PTEN</i> Mutations in Breast CancerJacqueline J Tao, Saumya D Sisoudiya, Hanna Tukachinsky, et al.
Cancer Research Communications|March 16, 2023
Real-world Validation of TMB and Microsatellite Instability as Predictive Biomarkers of Immune Checkpoint Inhibitor Effectiveness in Advanced Gastroesophageal CancerRyon P Graf, Virginia Fisher, James Creeden, et al.
Lung Cancer (Auckland, N.Z.)|May 31, 2018
Response to rapamycin analogs but not PD-1 inhibitors in PTEN-mutated metastatic non-small-cell lung cancer with high tumor mutational burdenAnkur R Parikh, Siraj M Ali, Alexa B Schrock, et al.
Cancer Research Communications|April 3, 2025
Diverse ERBB2/ERBB3 Activating Alterations and Coalterations Have Implications for HER2/3-Targeted Therapies across Solid TumorsDazhi Liu, Justin Jee, Alexander Drilon, et al.
The Oncologist|May 17, 2017
Detection of an <i>ALK</i> Fusion in Colorectal Carcinoma by Hybrid Capture-Based Assay of Circulating Tumor DNAAndrea Z Lai, Alexa B Schrock, Rachel L Erlich, et al.
JCO Precision Oncology|March 7, 2024
Association of Timely Comprehensive Genomic Profiling With Precision Oncology Treatment Use and Patient Outcomes in Advanced Non-Small-Cell Lung CancerJeff Yorio, Katherine T Lofgren, Jessica K Lee, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 27, 2016
Emergence of Preexisting MET Y1230C Mutation as a Resistance Mechanism to Crizotinib in NSCLC with MET Exon 14 SkippingSai-Hong Ignatius Ou, Lauren Young, Alexa B Schrock, et al.
The Oncologist|January 19, 2021
RAS Amplification as a Negative Predictor of Benefit from Anti-EGFR-Containing Therapy Regimens in Metastatic Colorectal CancerAlexa B Schrock, Jessica K Lee, Jaideep Sandhu, et al.
Pageof 13